Replies to post #117731 on Biotech Values

[jq1234]

They may run this up a while before they figure out it's way overvalued.

Exactly. Cheap can become cheaper, overvalued can become even more overvalued. In biotech, price can swing widely, with or without news. If you can take care of downside risk (clinical or regulatory failure), the rest can take care itself. So, I don't chase high flyers. There are tons of other promising ones with reasonable valuation. There will be opportunity to get in in the future in almost every one of them. There is only one exception, ALXN only goes one way, that is up. Incredible :-)